madman
Super Moderator
RALEIGH, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce a new partnership with Numan, a leading UK-based, VC-backed digital health platform, to introduce KYZATREX® (testosterone undecanoate) CIII capsules into Numan’s product offerings. KYZATREX is FDA-approved in the US and is indicated for adult men who have low or no testosterone due to certain medical conditions. This collaboration marks a significant step forward in the treatment of testosterone deficiency, offering men a more comprehensive and patient-centered solution for managing this common yet often overlooked condition.
Testosterone deficiency (TD) is a rising global epidemic, affecting approximately four in ten men over the age of 45 and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society.1,2 In the UK alone, it is estimated that around 3 million men suffer from testosterone deficiency, with around 90% of those cases remaining untreated.3-5 TD is bi-directional with metabolic diseases, and early research suggests it may play a role in further conditions such as depression and inflammatory diseases. As these health issues continue to escalate, the partnership between Marius Pharmaceuticals and Numan marks a collaborative effort to position KYZATREX as a promising solution in the fight against this widespread medical condition.
“We are thrilled to partner with Numan and expand the availability of KYZATREX to patients in the UK,” said Amit Shah, Chief Operating Officer at Marius. “Testosterone deficiency is a global health issue, and our collaboration allows us to offer men a therapy that is not only effective but also designed with patient safety in mind. By joining forces with a trusted health platform like Numan, we’re confident that more men will have access to the care they need to improve their overall health and well-being.”
KYZATREX has been specifically formulated to be gentle on the body, bypassing the liver to prevent potential liver damage, a common concern with other forms of testosterone therapy. In a six-month clinical trial involving 139 men with low testosterone, 88% of KYZATREX patients achieved normal testosterone levels by Day 90 (worst-case scenario calculation, excluding Site 104). For patients who completed the study (n=127), this number rose to 96%. Furthermore, KYZATREX patients experienced a twofold increase in Free Testosterone levels and a 30% reduction in Sex Hormone Binding Globulin (SHBG) levels.6-8
Numan, already a leader in the medical weight loss space in the UK, brings a unique, patient-focused approach to testosterone therapy. Their process includes a holistic, guideline-led diagnosis using gold-standard blood testing and expert analysis. By integrating KYZATREX into their offerings, Numan continues to expand its commitment to men's health, delivering tailored treatment programs that address the root causes of testosterone deficiency and support overall wellbeing.
